-
Mashup Score: 9Time to reframe the disease staging system for type 1 diabetes - 4 hour(s) ago
In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 diabetes. This model, based on islet autoantibodies (stage 1) and dysglycaemia (stage 2) before type 1 diabetes diagnosis (stage 3), has facilitated screening and identification of people at risk. Yet, there are many limitations to this model as the stages combine a very heterogeneous group of individuals; do not have high specificity for type 1 diabetes; can occur without persistence (ie, reversion to an earlier risk stage); and exclude age and other influential risk factors.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0Achievement of HbA1c targets: real-world data from international paediatric type 1 diabetes registries - 8 hour(s) ago
The St Vincent declaration1 calls for monitoring and comparing outcomes of diabetes care against treatment goals as a tool for quality control. National diabetes registries serve this purpose.2 In the past decade, lowering HbA1c targets in children with type 1 diabetes3 was a result of the overall improved HbA1c and, simultaneously, decreased incidence of severe hypoglycaemia.4 In the meantime, advances in diabetes technology have led to increased adoption of continuous glucose monitoring and insulin pump therapy,5 facilitating treatment among young people with type 1 diabetes.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Beate Karges & Mikael Knip comment on: Achievement of HbA1c targets: real-world data from international paediatric type 1 #diabetes registries https://t.co/SD6hYW3Ipe #T1D
-
-
Mashup Score: 3
Between 2013 and 2022, glycaemic outcomes have improved, parallel to increased use of diabetes technology. Many children had HbA1c higher than the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 target. Reassuringly, despite targeting lower HbA1c, severe hypoglycaemia event rates are decreasing. Even for children with type 1 diabetes who have access to specialised diabetes care and diabetes technology, further advances in diabetes management are required to assist with achieving ISPAD glycaemic targets.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 #diabetes (2013–22): a longitudinal analysis of data from paediatric diabetes registries https://t.co/DgjIKAzszj #T1D
-
-
Mashup Score: 86
In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 diabetes. This model, based on islet autoantibodies (stage 1) and dysglycaemia (stage 2) before type 1 diabetes diagnosis (stage 3), has facilitated screening and identification of people at risk. Yet, there are many limitations to this model as the stages combine a very heterogeneous group of individuals; do not have high specificity for type 1 diabetes; can occur without persistence (ie, reversion to an earlier risk stage); and exclude age and other influential risk factors.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New in the December Issue: Time to reframe the disease staging system for type 1 #diabetes https://t.co/2l3BfhYCKz #T1D https://t.co/ysLkEO7lsr
-
-
Mashup Score: 16
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
-
Mashup Score: 16Closed-loop systems: a bridge to cell therapy for type 1 diabetes? - 2 month(s) ago
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
-
Mashup Score: 16Closed-loop systems: a bridge to cell therapy for type 1 diabetes? - 2 month(s) ago
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
-
Mashup Score: 16Closed-loop systems: a bridge to cell therapy for type 1 diabetes? - 3 month(s) ago
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
-
Mashup Score: 16Closed-loop systems: a bridge to cell therapy for type 1 diabetes? - 3 month(s) ago
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
-
Mashup Score: 15Closed-loop systems: a bridge to cell therapy for type 1 diabetes? - 3 month(s) ago
Despite considerable advances in treatments and technologies for people with type 1 diabetes, the treatment framework has remained largely unchanged since insulin was discovered 100 years ago. While many innovations have delivered modest gains in reaching glycaemic targets and reducing diabetes-related complications, they often come with increased complexity and burden, and hypoglycaemia remains a serious issue. The emergence of automated insulin delivery (AID) systems have the potential to allow the achievement of optimal glycaemic targets with less burden, but in our view, it is not the ultimate solution.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Closed-loop systems: a bridge to cell therapy for type 1 #diabetes? https://t.co/YxWwD9eogL #T1D https://t.co/CxfBxlCHhD
-
New in the December Issue: Time to reframe the disease staging system for type 1 #diabetes https://t.co/2l3BfhYCKz #T1D https://t.co/ysLkEO7lsr